3B BlackBio Dx Ltd
1,332.95
INR
-16.35
(-1.21%)
3B BlackBio Dx Ltd
BSE:3BBLACKBIO
(Bombay Stock Exchange)
Recent
price
1,332.95
P/E
ratio
17.79
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- 3B BlackBio Dx Ltd is a biotechnology company that designs, develops, manufactures, and commercializes molecular diagnostic kits and related PCR-based solutions, with a focus on rapid tests, qPCR assays, enzymes and reagents, and next-generation sequencing (NGS) based diagnostics. The company operates across diagnostics and molecular testing, offering a broad portfolio under TRUPCR and related brands, and supplies products to clinical laboratories and healthcare providers domestically in India and internationally through a growing network of channel partners and registrations in multiple jurisdictions. Headquartered in Bhopal, India, the company was established in 2011 and maintains manufacturing and R&D capabilities to support design, development, and commercialization of diagnostic kits and related molecular biology products. Main products and services: - PCR based Molecular Diagnostic Kits (rapid tests, qualitative and quantitative PCR kits) and accompanying enzymes and reagents - Design, development, manufacturing, and commercialization of molecular diagnostic assays for infectious diseases and oncology indications - NGS-based molecular diagnostic panels and extraction kits for sample processing - Brand portfolio including TRUPCR branded kits and related molecular biology products - Regulatory and quality-compliant manufacturing operations aligned with ISO 13485:2016 and GMP standards - International sales through contract manufacturing, distribution channels, and partner networks - Technical services and support for validation, troubleshooting, and assay deployment across laboratories Latest major company changes: - Expansion of international distribution through new channel partnerships across multiple countries to broaden global market reach - Completion of product registrations in several target markets with ongoing regulatory filings in additional regions to facilitate market access - Introduction and enhancement of Next-Gen Sequencing (NGS) based diagnostic offerings, expanding the product portfolio beyond PCR-based kits - Strategic emphasis on international tenders and collaborations to augment global supply and serve international diagnostics labs - Ongoing operational expansion of manufacturing and R&D capabilities to support a wider range of molecular diagnostics products - Continued focus on strengthening the regulatory compliance framework and quality management across markets Additional context: - Industry and segments: molecular diagnostics, PCR kits, rapid tests, reagents and enzymes, NGS-based diagnostic solutions - Target markets: clinical laboratories, diagnostic centers, hospitals, research laboratories, international markets through distributors and tenders - Geographic operations: primarily India with growing international presence through registrations, partnerships, and distribution networks; manufacturing and R&D located in India - Founding year and headquarters: founded in 2011; headquarters in Bhopal, Madhya Pradesh, India - Subsidiaries/relationships: operates as a biotech R&D and manufacturing organization; forms part of an Indo-Spanish collaboration in diagnostics and has channel partnerships to extend global reach